Soliqua is insulin glargine and lixisenatide; various forms of insulin are available - see other insulin profiles for reaction details.
insulin glargine-yfgn (Semglee) is biosimilar. Approved 07/28/2021
Insulin glargine-aglr (Rezvoglar) is biosimilar. Approved 12/17/2021
Litt's app available free to subscribers - download for IOS and Android from the App Store or Google Play.
- TRADE NAMES: Basaglar (Lilly); Lantus (Sanofi-Aventis); Soliqua (Sanofi-Aventis)
- INDICATIONS: Diabetes (Type I or II)
- CLASS: Hormone analog, polypeptide
- HALF-LIFE: N/A
- FDA APPROVAL DATE: 4/20/2000
- CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:
ACE inhibitors, Albuterol, Alcohol, Beta blockers, Clonidine, Clozapine, Corticosteroids, Danazol, Disopyramide, Diuretics, Epinephrine, Estrogens, Fibrates, Fluoxetine, Glucagon, Guanethidine, Isoniazid, Lithium, MAO inhibitors, Niacin, Olanzapine, Oral antidiabetic products, Oral Contraceptives, Pentamidine, Pentoxifylline, Phenothiazine derivatives, Pramlintide, Propoxyphene, Propranolol, Protease inhibitors, Reserpine, Salicylates, Somatostain analogs, Somatropin, Sulfonamide antibiotics, Terbutaline, Thyroid hormones
Please login to view the rest of this drug profile.
Click on the DRUG REVIEW ARTICLE tab (above) to see a review of insulin glargine in the Taylor & Francis journal Expert Opinion on Drug Safety.
(Note that non-subscribers to the journal will only be able to see an abstract of the article.)
Page last updated 05/30/2024
